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Abstract
Introduction: Irritable bowel syndrome affects as many as 14% of high school-aged students. Symptoms include
discomfort in the abdomen, along with diarrhea and/or constipation and other gastroenterological symptoms that
can significantly impact quality of life and daily functioning. Emotional stress appears to exacerbate irritable bowel
syndrome symptoms suggesting that mind-body interventions reducing arousal may prove beneficial. For many
sufferers, symptoms can be traced to childhood and adolescence, making the early manifestation of irritable bowel
syndrome important to understand. The current study will focus on young people aged 14-26 years with irritable
bowel syndrome. The study will test the potential benefits of Iyengar yoga on clinical symptoms, psychospiritual
functioning and visceral sensitivity. Yoga is thought to bring physical, psychological and spiritual benefits to
practitioners and has been associated with reduced stress and pain. Through its focus on restoration and use of
props, Iyengar yoga is especially designed to decrease arousal and promote psychospiritual resources in physically
compromised individuals. An extensive and standardized teacher-training program support Iyengar yoga’s reliability
and safety. It is hypothesized that yoga will be feasible with less than 20% attrition; and the yoga group will
demonstrate significantly improved outcomes compared to controls, with physiological and psychospiritual
mechanisms contributing to improvements.
Methods/Design: Sixty irritable bowel syndrome patients aged 14-26 will be randomly assigned to a standardized
6-week twice weekly Iyengar yoga group-based program or a wait-list usual care control group. The groups will be
compared on the primary clinical outcomes of irritable bowel syndrome symptoms, quality of life and global
improvement at post-treatment and 2-month follow-up. Secondary outcomes will include visceral pain sensitivity
assessed with a standardized laboratory task (water load task), functional disability and psychospiritual variables
including catastrophizing, self-efficacy, mood, acceptance and mindfulness. Mechanisms of action involved in the
proposed beneficial effects of yoga upon clinical outcomes will be explored, and include the mediating effects of
visceral sensitivity, increased psychospiritual resources, regulated autonomic nervous system responses and
regulated hormonal stress response assessed via salivary cortisol.
Trial registration: ClinicalTrials.gov NCT01107977.
Introduction
The impact of IBS
IBS is a complex, chronic, functional disorder for which
there is no cure. The condition is characterized by
abdominal pain/discomfort and altered bowel habits;
other symptoms may include nausea, vomiting, and
bloating. IBS prevalence estimates in North America for
adults and adolescents are between 10 -15% [1,2]. Boys
and girls appear to be equally affected until late adoles-
cence [3], when sex differences emerge and women are
twice as likely to be affected as men [4]. Direct costs of
IBS to the U.S. health system are in the region of $10
billion, with indirect costs contributing a further $20 bil-
lion [5]. IBS and related functional bowel disorders have
been ranked as a common cause of illness-related absen-
teeism, second only to the common cold [6]. In addition
to increased healthcare use and absenteeism, IBS has
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been related to an elevated risk of other somatic intest-
inal and extraintestinal comorbidities, psychological
comorbidities such as anxiety and depression [7], and to
reduced quality of life [8].
There are no definitive biochemical, structural or ser-
ologic markers to assist diagnosis or assessment of
treatment efficacy [9]. Currently, symptom-based
approaches are used in diagnosis and the Rome criteria,
now Rome III [10], is the current gold standard of diag-
nostic tools. The Rome diagnostic criteria presume the
absence of a structural or biochemical explanation for
the symptoms, and diagnosis is made by an experienced
clinician. ROME III criteria consist of recurrent abdom-
inal pain or discomfort for at least 3 months, onset at
least 6 months previously and with at least two of the
following: improvement with defecation, onset asso-
ciated with a change in frequency of stool, and/or onset
associated with a change in appearance of stool. Sub-
categories are based on stool consistency as IBS with
constipation, IBS with diarrhea, or IBS with mixed or
alternating constipation and diarrhea [11]. Criteria exist
for both children (4-18 years of age) and adults (over
18 years of age).
Although IBS is typically diagnosed in adults between
30 and 50 years of age [12], symptoms generally present
earlier, beginning in childhood and adolescence and
continuing through to adulthood [13]. Adolescence
represents a particularly important time in the develop-
ment of IBS symptoms. Prevalence estimates suggest an
increase from around 8% in middle school to 14% in
high school-aged students- a prevalence rate similar to
that seen in adult populations [3]. Given the often pro-
tracted course of IBS, it is important to study the emer-
gence of IBS and treatment options in young
populations. Quality of life is also greatly compromised
in young IBS sufferers. Varni and colleagues [14] found
that IBS significantly affected physical, emotional, social,
and school functioning in children and adolescents aged
5-18 years. In this study, children and adolescents were
more likely to miss school, spend days sick in bed, be
too ill to play, and need someone to care for them than
were healthy children.
It is likely that IBS takes a particular toll on the school
and social functioning of adolescents and early adults,
when dating, social acceptance and academic perfor-
mance become paramount concerns. Fear of pain, bloat-
ing, and/or diarrhea may severely limit the adolescent
patient’s willingness to attend school and social outings.
Yet engagement in such activities may be vital for future
functioning. Perceived academic competence has been
found to moderate the relationship between symptoms
and disability in adolescents with IBS, such that the rela-
tionship between symptoms and disability was strongest
when perceived competence was low [15]. Adolescents
with IBS are also more likely to experience depression
and anxiety than are healthy counterparts [3], co-mor-
bidities that may further impact quality of life and
exacerbate IBS symptoms. As reviewed below, the roles
of stress and psychosocial variables are becoming appar-
ent in current conceptualizations of symptom mainte-
nance. Over time, distressing symptoms may increase
because the IBS itself can become a significant source of
anxiety and fear of pain [16].
In the proposed study, late adolescence and early
adulthood was chosen as the target age range in part
because of the significant impact of IBS on school and
social life as well as the increased level of independence
during this period. In California, adolescents are able to
drive at 16 years of age. Given that attendance at a
group intervention involves transportation considera-
tions, it is likely that independent access to transporta-
tion would increase ease of attending the yoga sessions.
Pathophysiology of IBS
Complex neurophysiological and psychological pathways
underlie the experience of IBS. It is now generally
recognized that intimate interconnections exist between
the enteric motor system and the central nervous sys-
tem, termed the brain-gut axis, and that these intercon-
nections are involved in altered perception of visceral
events, the hallmark of IBS. Although small intestinal
bacterial overgrowth (discussed in detail below) has
been implicated in alterations in brain-gut communica-
tion, visceral hyperalgesia and gut motility remain the
primary “biomarkers” for the condition [17].
Visceral hyperalgesia is a consistent physiologic find-
ing in a majority of patients with IBS [18] and is a lead-
ing explanatory hypothesis [19]. Sensitivity of visceral
afferent pathways or central amplification of visceral
input is thought to be related to enhanced perception of
visceral stimuli [20,21]. This altered perception of visc-
eral stimuli may translate as hypervigilance, visceral
hypersensitivity, and increased autonomic arousal [22].
Under the brain-gut model, enhanced responsiveness of
central stress circuits is related to psychosocial and visc-
eral stressors, leading to IBS symptoms. The model
describes a relationship between altered cognitive pro-
cesses, such as anxiety and hypervigilance, and increased
ANS arousal, leading to increased visceral sensitivity and
IBS symptoms, which can in turn feed back into further
perceived stress and symptoms [16,23]. Support for the
role of psychological processes in symptom maintenance
is derived from studies showing that stressful life events
exacerbate IBS symptoms [24]; and mild psychological
stress increases visceral perception in IBS patients but
not healthy controls [25]. Recently, psychosocial risk
markers, including illness behavior, anxiety, sleep pro-
blems, and somatic symptoms, were found to be
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independent predictors of IBS onset in subjects pre-
viously free of IBS [26].
ANS dysregulation may at least partially mediate the
brain-gut axis. Findings suggest that many IBS patients
have altered autonomic responsiveness to visceral stres-
sors, with increased sympathetic and decreased para-
sympathetic activity, as noted through heart rate
variability (HRV) parameters, compared to controls [27].
Thus, cardiac autonomic system activation, demon-
strated by HRV parameters, may be a plausible evalua-
tion of autonomic balance related to ANS activity in IBS
symptoms [28]. However, IBS characteristics may mod-
erate the role of cardiac vagal tone. ANS imbalances
may only be present in 25% of patients and could vary
as a function of IBS severity and type (constipation- ver-
sus diarrhea-predominant) [29]. As discussed below,
yoga is likely to improve functioning in IBS patients
through a variety of mechanisms, including improved
psychospiritual functioning and reduced visceral sensi-
tivity, in addition to more regulated ANS reactivity for
those patients with ANS imbalance. Thus, it is antici-
pated that yoga will prove beneficial for IBS patients
regardless of IBS characteristics and ANS dysregulation.
The hypothalamic-pituitary-adrenal (HPA) axis may
also be implicated in symptoms, but research in this
regard is equivocal [30,31]. In a recent study comparing
cortisol in women with and without IBS, a trend
emerged for increased plasma cortisol levels in the IBS
group, although cortisol levels were not associated with
current IBS symptoms. These results suggest that HPA
axis dysregulation may not play a primary role in modu-
lation of symptoms, but rather, indicate generalized
upregulation of the central stress system and reduced
state of well-being for a range of stress-related disorders
[32]. Thus, cortisol will be included in the study as a
measure of change in stress and not a specific neuro-
enteric mechanism.
A role for small intestinal bacterial overgrowth (SIBO)
has emerged suggesting that gastrointestinal (GI) infec-
tion can induce long-term inflammatory changes in the
GI tract that may be relevant for a sub-group of patients
with IBS. It has been found that IBS patients have sig-
nificantly more SIBO than controls [33] and changes in
GI function, such as increased GI permeability, have
been reported [34], which may at least partially be
caused by a genetic predisposition for reduced anti-
inflammatory cytokines [35]. However, it has recently
been argued that the presence of SIBO in IBS patients is
not fundamental to IBS pathophysiology and may be a
by-product of an increased use of proton pump inhibi-
tors [36]. Given discrepancies in whether SIBO repre-
sents a distinct pathogenesis, and the current standard
of using visceral hyperalgesia as a surrogate biomarker,
all qualified potential subjects with diagnosed IBS will
be included in the present study, and the same out-
comes and mediators will be tested regardless of
etiology.
The inclusion of a test of visceral sensitivity, the
Water Load Task (WLT), is an innovative aspect of the
present study. To date, no research has examined biolo-
gical changes in IBS patients following mind-body inter-
ventions. Although visceral hyperalgesia may be a
somewhat unreliable biological marker compared to
those applicable in other diseases, it has been recom-
mended as an important outcome for IBS clinical trials
[17]. The WLT also provides a stimulus to assess
change in ANS response following IY.
Standard medical treatments are limited
Given the chronic nature of IBS, by definition, therapy is
generally protracted. It is recommended that the chronic
use of drugs be minimized or avoided because of the
lifelong nature of IBS and lack of convincing evidence
regarding the therapeutic benefit of current IBS drugs
[37]. A recent Cochrane review found no clear evidence
that fiber supplements, lactose-free diets, or lactobacillus
supplements assist with the management of pediatric
recurrent abdominal pain (RAP) [38]. Additional consid-
erations exist for young patients. For example, parents
appear averse to children using medications such as
antidepressants to treat IBS [39].
Mind-body approaches to address IBS symptoms and
quality of life are currently of interest [16] and may
prove to complement existing medical treatments.
Clinical studies have demonstrated the value of hyp-
notherapy, cognitive-behavioral therapy, and brief psy-
chodynamic therapy. A recent randomized controlled
trial (RCT) used four 90-minute relaxation training ses-
sions incorporating progressive muscle relaxation and
breathing in a group of 98 adult IBS patients [40]. Com-
pared to the standard treatment controls, the relaxation
group evidenced significantly improved IBS symptom
severity and quality of life, and reduced medical visits.
In a recent RCT with 53 pediatric patients, gut-directed
hypnotherapy was found to have long-term efficacy for
children with IBS and RAP and was significantly more
effective than standard medical treatment in reducing
symptoms; 85% of patients treated with hypnotherapy
were in clinical remission, defined as at least an 80%
decrease in pain, at a one-year follow-up compared to
25% of the standard care group [41]. Despite the pro-
mise of mind-body treatments for functional disorders,
there is limited research into approaches such as mind-
fulness and yoga.
Yoga as treatment for IBS
Yoga is a discipline developed in ancient India, incor-
porating and uniting principles of posture, breathing,
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and meditation, thought to bring physiological and psy-
chological benefits to practitioners. Characterized as a
science of self-study and the development of awareness
through a series of specific asanas (body postures), pra-
nayama (proscribed breathing patterns), and meditation,
yoga has been embraced in modern Western settings as
a form of exercise and stress reduction. Currently, yoga
programs are relatively low cost, widely available in the
form of classes or through home video/book programs,
and, when performed properly, have little risk of adverse
effects. Nevertheless, there is a dearth of well-designed
RCTs on the specific effects of yoga for chronic pain
conditions, particularly among children and adolescents.
Reduced pain and disability and increased quality of
life have been reported in RCTs of yoga for various con-
ditions in adults, including migraines and headaches
[42,43], rheumatoid arthritis [44], osteoarthritis [45] and
chronic low back pain [46]. A review of the literature on
yoga for cancer [47] concluded that yoga interventions
consistently yield modest improvements across a range
of outcomes, including psychological (mood, distress,
stress) and somatic (e.g., sleep disturbance) symptoms.
Other reviews of yoga for pain, disability, and quality of
life [48], as well as depression [49] and anxiety [50],
have noted that yoga appears to enhance physical and
psychological functioning, although much of the litera-
ture is limited by methodological problems, including
small sample sizes, unclear description of randomiza-
tion, and lack of control groups.
Only two studies have focused on the use of yoga for
IBS. Kuttner and colleagues [51] provided the only trial
of yoga for pain conditions in children and adolescents
(25 IBS patients aged 11-18 years). However, this limited
intervention consisted of a 4-week home-practice of
yoga, subsequent to an initial training session. It is
unclear to what degree participants actually practiced
yoga and to what extent they adhered to the prescribed
yoga protocol. Despite these limitations, Kuttner et al.
found that the yoga group exhibited significantly
improved post-study IBS symptoms and significantly
reduced disability, coping, and anxiety relative to wait-
list controls. The only other study that examined yoga
for IBS found improved parasympathetic reactivity in a
small group of 20-50 year-old males undergoing
biweekly yoga classes for 8 weeks compared with an
intervention group administered loperamide (2-6 mg/
day) [52]. One limitation was the lack of a non-interven-
tion control group. Before novel therapies can be com-
pared to current treatments, it is recommended that
efficacy first be established in comparison to non-inter-
vention controls [53]. Both the medication and yoga
groups improved equally on decreasing bowel move-
ments and anxiety, indicating yoga may be similar to
standard pharmacological intervention. The study also
included autonomic responses to a cold pressor task
and found no differences between the medication and
yoga groups, although neither behavioral nor self-report
pain responses to the task were assessed. The yoga
group, however, showed significantly enhanced parasym-
pathetic reactivity, as measured by HRV, when com-
pared to controls at the end of the second month of
yoga, indicating a decrease in stress response. However,
the study was small (n = 9 for the yoga group), studied
only male patients even though the majority of adult
IBS patients are female, only included diarrhea-predomi-
nant IBS, and employed abbreviated health and func-
tioning assessments. Although limited, the findings
suggest that yoga may be at least as effective as medica-
tion in alleviating IBS-related diarrhea and anxiety, with
additional stress-reduction benefits.
The present study will address a number of the limita-
tions of previous studies. Primarily, the current sample
will be sufficiently large to detect treatment effects (see
Power analyses below) and will involve an RCT with an
appropriate control group for this stage of the clinical
trial process. The selection of a wait-list control condi-
tion was based upon consideration of the literature and
a lack of consensus regarding an acceptable attention
control condition to compare to yoga. In this prelimin-
ary study, the control group will involve patients receiv-
ing care as usual for the length of the yoga intervention.
Symptoms, physical activity, and lifestyle changes will be
assessed weekly in both the yoga and control groups.
While the control group will not account for the social,
attention, or expectation aspects of the IYP, a usual care
control group is appropriate at this stage of the research
when examining a novel treatment in an untested popu-
lation. If the IYP is found to be superior to the wait-list
group in this exploratory study, a future R01 will incor-
porate a control condition that accounts for the social,
attention, and expectation effects of a group-based
intervention.
Other strengths of the study include the testing of
psychophysiological mechanisms of action based on our
published model of yoga (see figure 1) [54]. In addition,
this investigation unlike previous studies will take devel-
opmental issues into account. This study will be limited
to later adolescence and early young adulthood. In order
to enhance scientific generalizability and the actual prac-
tice of yoga, it is important to target an age-range that
represents similar challenges. For example, older IBS
patients will likely have differences in motility, flexibility,
and confidence compared to a younger group. A num-
ber of reasons underlie the focus on 14-26 year-olds.
First, this group is likely to experience similar develop-
mental challenges, including adjustments in a sense of
self, family, schooling, and peers [55]. The primary stres-
sors for most young people of this age-range relate to
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academic and social performance and increasing levels
of autonomy. Second, the level of independence during
this period will increase retention of subjects. In Califor-
nia, adolescents are able to drive at 16 years of age.
Given that attendance will involve transportation con-
siderations, it is likely that independent access to trans-
portation will increase ease of attending the yoga
sessions. Third, the target age range reflects the peak in
IBS prevalence that remains relatively consistent across
adulthood. During high school, IBS rates increase to
adult levels of 15%, from around 8% earlier in childhood
[3]. This suggests a developmental shift in the illness
around adolescence. It is therefore likely that the IBS
symptoms experienced by older adolescents will be
comparable to those experienced by college-aged young
adults. Overall, it is anticipated that the IYP will have
similar benefits for adolescents and young adults across
the age group studied. Despite the likelihood that IY
will prove useful for both adolescents and young adults,
consideration will be given to sub-groups within the
age-range. It is possible that a 14-26 year-old range
crosses important developmental challenges (e.g., enter-
ing college), and results will therefore be examined sepa-
rately for a 14-18 year-old adolescent sub-group and a
19-26 year-old young-adult sub-group. Thus, feasibility,
efficacy, and safety will be examined separately for ado-
lescents and young adults, and only if the sub-groups
respond similarly to the intervention will final analyses
collapse the groups. Such a developmentally-sensitive
approach has not been used in yoga research to date.
Unlike most other studies that have failed to specify
the yoga tradition utilized, a planned, standardized inter-
vention from the IY tradition will be employed. IY has
been beneficial in treating a range of chronic medical
conditions [48] and is likely to be particularly suitable
for IBS patients. Sequences are tailored for specific con-
ditions, teachers have extensive training in anatomy,
physiology, and safety, and the use of props allows poses
to be held without strain or fear of injury. The emphasis
on alignment in the IY tradition is unique, and it is
believed that maintaining poses with effort on under-
standing alignment strengthens muscles, organs, and
joints, and develops mindfulness of poor posture or
gripping of tension in the body [56]. IY is one of a few
forms of systemized yoga that involves extensive teacher
training. Teacher training occurs in one of 16 Iyengar
yoga associations around the world. Under the guidance
of Mr. Iyengar, the associations have devised teacher
training courses with detailed guidelines on require-
ments for enrolling, the training syllabus, stages of
assessment, awarding certificates, and maintaining certi-
fication. Teachers study for at least seven years before
being certified to work with students who have thera-
peutic needs. Tests for certification include teaching,
performance of poses and breathing techniques, anat-
omy, and therapeutic sequences. The detailed sequences
of postures tailored for specific health conditions and
the rigorous teacher training program suggest IY is par-
ticularly suitable for use in clinical trials.
Biopsychosocial model of chronic pain
The conceptual model for the present study is built
within the biopsychosocial model of chronic pain [57].
The frequent co-occurrence of affective disorders, other
functional GI disorders, and non-GI complaints suggests
that the maintenance and treatment of IBS can best be
understood using a biopsychosocial model [16]. It is
likely that biological factors such as genetics and visceral
Psychological  
Self-efficacy 
Coping
Positive Mood 
Spiritual 
Acceptance 
Mindfulness 
Iyengar Yoga 
Physiological 
ANS arousal (blood pressure, 
respiration, skin conductance, 
heart rate) 
HPA reactivity (cortisol) 
Primary Outcomes 
Improved IBS symptoms 
Improvements in HRQOL 
Global Improvement
Reduced Visceral Sensitivity
Mediators
Figure 1 Conceptual model of Iyengar yoga for IBS.
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hypersensitivity along with psychological and lifestyle
factors all contribute towards IBS-related pain and func-
tioning. Twin studies have shown that while genetics
play an important role in IBS symptoms, environmental
factors such as social learning contribute an equal or
even greater etiological influence [58]. Thus, an integra-
tive treatment strategy for patients with IBS is
warranted. IY represents a non-pharmacological inter-
vention that can be integrated into a conventional treat-
ment plan. Within the conceptual model below, IY is
viewed as impacting IBS symptoms and pain through
physical, psychological, and spiritual mediators. Such
examination of mediators has been deemed critical, both
for understanding treatment components as well as to
further our knowledge of functional disorders [59].
Derived from the biopsychosocial model of pain and
yoga philosophy, Figure 1 depicts a conceptual model of
how IY may improve IBS pain, functioning, and stress.
The model offers a guiding heuristic for conceptualizing
the benefits of IY for IBS; the model does not depict all
possible pathways across domains. The outcomes in the
model represent the study’s primary outcomes, and the
physiological, psychological, and spiritual mechanisms
represent the exploratory mediators to be tested.
Physiological mechanisms
It is thought that yoga quiets the body as well as the
mind through attention and vascular and muscular
relaxation [60]. Yoga has been associated with a number
of physiological benefits. Research linking yoga with
ANS functioning has found improved physiologic
responses, including reduced diastolic and systolic blood
pressure, decreased heart rate, and increased heart rate
variability, indicative of healthy functioning [61-64]. IY
appears to be especially involved in enhancement of car-
diac parasympathetic system modulation, consistent
with a reduction in stress response pathophysiology
[64]. It is possible that breath awareness during yoga
produces a high level of autonomic control. For exam-
ple, after a month of yoga practice, a group of 12
healthy participants had a lower resting heart rate after
the intervention compared to a group of 12 controls;
individuals in the yoga group were also able to signifi-
cantly lower their heart rates when given instruction to
do so [65]. It is unknown whether similar autonomic
enhancement will be evident in young IBS patients;
however, biofeedback, which incorporates autonomic
control, has been used successfully with children as
young as 8 years of age [66]. Yoga may also impact the
endocrine system and HPA reactivity. It is believed that
asana practice massages the internal organs, resulting in
enhanced blood circulation, glandular functioning, and
ultimately balancing of hormone production [60]. A
number of studies have found changes in cortisol, a
measure of stress response system activation, following
yoga [67-69]. The physiological benefits of yoga may
prove beneficial to many IBS patients, particularly those
with ANS and HPA axis dysregulation. Accordingly,
cortisol, ANS arousal, and visceral sensitivity will be
measured before and after the intervention and com-
pared to the standard care controls.
Psychological mechanisms
Yoga has a number of positive effects on psychological
functioning that have been reported in healthy, pain,
and stress groups and for a wide variety of age groups.
Two recent reviews examining yoga for depression and
anxiety underscored the promise of yoga for elevating
mood. Out of five RCTs of yoga for depression, benefi-
cial effects were reported in four [49]. All eight rando-
mized studies of yoga for clinical anxiety disorders
reported a reduction in symptoms following yoga [50].
For example, Woolery et al. [67] reported reduced
depression and anxiety after a 5-week IYP in depressed
young adults. Similarly, Shapiro [70] found that a 20-
week IYP led to reductions in depression, anger, anxiety,
and neurotic symptoms in 17 patients with major
depression (aged 20-71 years). Other positive psycholo-
gical effects include coping and self-efficacy. Adolescents
with IBS were found to have reduced anxiety and less
emotion-focused coping following four weeks of home-
practice yoga [51]. Persisting in a yoga class promotes a
sense of accomplishment that is consistent with the
development of self-efficacy. Given the previous role of
competence in the link between adolescent IBS patients’
symptoms and disability [15], it is likely that a sense of
mastery achieved through yoga will positively impact
symptoms. Self-efficacy, effective coping, and positive
psychological functioning, in turn, are related to better
physical functioning in patients experiencing chronic
pain and illness [71]. Thus, it is anticipated that yoga
will enhance patients’ coping, psychological functioning,
and self-efficacy, all of which are expected to mediate
the hypothesized improvement in clinical symptoms fol-
lowing the IYP.
Spiritual mechanisms
Related to the psychological benefits of yoga are the
spiritual underpinnings of yoga. Spirituality and well-
being appear to be connected, particularly in those
experiencing chronic illnesses [72]. Two aspects of spiri-
tuality that IY is likely to impact are mindfulness and
acceptance, both of which will be tested as mediators in
the present study. IY is associated with a mastery of life
challenges, which may extend to dealing with chronic
illness and pain [73]. As noted by BKS Iyengar, “The
pain is there as a teacher... We must try not to run
from pain but to move through it and beyond it” [74]. It
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is anticipated that the IYP will enhance patients’ com-
passionate understanding, an Eastern concept that in
this context can be conceptualized as compassion
towards oneself or acceptance (i.e., acceptance of one’s
health condition). Such acceptance or understanding of
one’s state appears to be important for those with
chronic pain [75]. IY is also associated with mindful
awareness, a concept that has been integrated in empiri-
cally-validated approaches including cognitive-behavioral
therapy [76]. Mindfulness is an openness or receptive
awareness to what is occurring in the present. Mindful
activity has been found to improve mood and stress [77]
likely through strengthening attention [60]. Use and
control of attention can be turned towards minimizing
stress, disability, and pain. It has been theorized that
mindfulness may be especially effective in treating func-
tional disorders such as IBS [16]. It is anticipated that
IY will lead to an increase in mindfulness and accep-
tance which will in turn improve functioning among
young IBS patients.
Aims
The purpose of the proposal is two-fold: 1) to examine
the effects of an IYP on IBS symptoms, global improve-
ment, and quality of life in adolescents and young adults
aged 14-26; and 2) to explore the mediating roles of
physiological and psychospiritual processes through
which IY is likely to impact outcomes.
The specific aims of the proposed project are:
1. To determine the safety, feasibility, and acceptabil-
ity of the IYP in IBS patients aged 14-26 years.
2. To test for changes in clinical symptoms (primary
outcomes), including self-reported IBS symptoms,
global improvement, and health-related quality of
life (HRQOL) immediately following a standardized
IYP and at 2-month follow-up compared to usual
care wait-list controls.
3. To assess changes in visceral sensitivity (assessed
via a standardized laboratory visceral sensitivity
task), disability and psychospiritual functioning (i.e.,
catastrophizing, mood, self-efficacy, acceptance, and
mindfulness) (secondary outcomes) following the
IYP compared to controls.
4. To explore potential mediators of clinical out-
comes following the IYP, including psychospiritual
functioning, visceral sensitivity, and ANS and HPA
activity.
The hypotheses to be tested are:
1. The IYP will be safe, acceptable and feasible: at
least 80% of subjects will complete the IYP.
2. Following the IYP, participants will demonstrate
significantly greater improvement on the primary
clinical outcomes of IBS symptoms, global improve-
ment, and HRQOL relative to wait-list controls;
gains will also be evident at the 2-month follow-up.
3. Following the IYP, participants will demonstrate
significantly reduced visceral sensitivity and disabil-
ity, and improved psychospiritual functioning,
including coping, mood, self-efficacy, acceptance,
and mindfulness (secondary outcomes) relative to
wait-list controls.
4. Exploratory hypothesis: The impact of the IYP on
the primary clinical outcomes will be mediated by
improved psychospiritual functioning, reduced visc-
eral sensitivity, and improvements in ANS and HPA
dysregulation.
Research design and methods
Design
A randomized control design will be used to examine
the impact of IY for youth aged 14-26 years with IBS on
the following outcomes: IBS symptoms, global improve-
ment, HRQOL, and laboratory pain sensitivity. The
study design is depicted in Figure 2. After baseline
assessment, including standardized questionnaires and
the laboratory visceral task (including ANS/psychophy-
siological measurements and cortisol collection), partici-
pants will be randomly assigned to the IY program or
the wait-list control group. It is anticipated that rando-
mization will ensure equal distribution of males and
females, adolescents and young adults, and symptom
severity across groups. Baseline assessments will be
completed in order to ensure that the yoga and control
groups are comparable, and to test for pre/post changes
in the yoga group.
Randomization
A research assistant who is not otherwise involved in
the yoga study, and who has not met or had previous
contact with any of the subjects, will use the Research
Randomizer program as a means to generate random
numbers (either 0 or 1) for patient assignment to the
intervention or wait-list group. The program uses a
JavaScript random number generator to produce custo-
mized sets of random numbers, which are then down-
loaded in an Excel database. Patients who have been
screened and have entered the study will be listed in the
recruitment database. This list of participants will be
aligned with the output of random numbers. Patients
with a number less than 0.5 will be assigned to the
intervention group and those with a number greater
than 0.5 will be assigned to the wait-list group. Consis-
tent with the need to ensure allocation concealment
[78], the randomization results will be kept in a secure,
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locked, password-protected Excel database that only the
research assistant has access to.
Female participants will provide information on their
last menstrual period during the baseline questionnaire
and laboratory session, and where possible, their post-
intervention questionnaire and laboratory session will be
scheduled to take place during the same cycle phase as
their baseline session (e.g., follicular vs. luteal phase).
Pain may vary for women along with their menstrual
cycle, both for laboratory pain tasks [79] and for general
IBS symptoms [80]. It is therefore important to ensure
that any change experienced by female patients after the
IYP is not the result of completing the laboratory task
during a more/less sensitive phase of their cycle.
Those initially assigned to IY will then engage in the 6-
week biweekly program (each session will last 1.5 hours;
total duration = 18 hours), while those assigned to the
control group will receive care as usual. All participants
will repeat the baseline assessments, including the sensitiv-
ity task and psychophysiological assessment and cortisol
collection, immediately following the total treatment/con-
trol period. Questionnaires regarding symptoms will also
be e-mailed at a 2-month post-treatment follow-up. Both
the yoga and control groups will receive a weekly monitor-
ing form to assess symptoms, physical activity, and lifestyle
changes (and to ensure that the control group does not
participate in any mind/body interventions that may
impact findings). The weekly monitoring form will be
administered by phone or e-mail to both groups at the
end of each week. After the 6 weeks, controls will be re-
assessed to ensure that they still meet study eligibility cri-
teria; those who continue to meet criteria will take part in
the IYP. Following IY, participants will repeat the baseline
assessments at post-treatment and complete the 2-month
post-treatment follow-up questionnaires.
According to the Power/Sample Size calculations out-
lined below, 30 patients in each of the intervention and
control groups will be recruited (total n = 60). To
accommodate this number, 4 IY groups and 4 initial
control groups will be conducted, with approximately 8
patients per group.
Study participants
Enrollment criteria
Male and female youth will be eligible for the study if
they meet the following criteria:
• Age 14-26 years.
• Diagnosis of IBS, using ROME III pediatric criteria
for patients aged 14-17 years, and ROME III adult
criteria for 18-26 year-olds.
• Able and willing to give written informed assent or
consent and comply with the requirements of the
study protocol.
• Ability to speak and understand English.
Every step will be taken to ensure that equal numbers
of participants make up the sub-groups, including equal
numbers of young men and women and young people
across the entire age group studied.
Exclusion criteria
Patients will be excluded from the study based on the
following criteria:
• History of drug, alcohol, or chemical abuse within
6 months prior to screening.
• Any other injury, disease, metabolic dysfunction,
physical examination finding, or clinical labora-
tory finding giving reasonable suspicion that it
might affect the interpretation of the results or
Baseline Assessment
Control Group Yoga Group 
Post Assessment 
Re – assessment for eligibility
Follow-up Assessment 
6 weeks usual care
6 weeks IY 
Weekly monitoring form
8 weeks 
Yoga
Post Assessment 
Follow-up Assessment 
8 weeks 
6 weeks IY 
Figure 2 Flowchart of study design.
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render the patient at high risk from treatment
complications.
• Inability to comply with study and follow-up
procedures.
• Currently pregnant.
• Previous practice of IY within the past three
months.
• Inability to speak and understand English.
• Plan to begin a new treatment within 2 weeks of
the IYP.
Because a number of the outcome measures have been
validated in English only and the IY protocol is only in
English, for this initial study only those patients able to
speak or understand English will be included. However,
in future large-scale trials, Spanish speaking individuals
will be included and we will translate and back-translate
the questionnaires into Spanish if no Spanish versions
exist, as well as develop yoga protocols that are in Span-
ish, and employ Spanish speaking IY teachers. We will
ask participants whether they are pregnant at the time
of study entry; however, the IY classes will not contain
poses that are harmful to pregnant women. Substance/
alcohol abuse, as well as practice of yoga, will be
assessed via self-report. Although subjects will not be
excluded if they begin new treatments during the IYP,
those subjects who are planning on introducing new
treatment 2 weeks or less before the IYP commences
will be excluded. These patients will be offered partici-
pation in the next round of IY classes.
Recruitment
Participants will be recruited from the pediatric gastro-
enterology clinic and the UCLA Center for Neurobiol-
ogy of Stress (CNS) in the Division of Nutrition and
Digestive Disease at the David Geffen School of Medi-
cine at UCLA, as well as from the UCLA Pediatric Pain
Program (PPP) clinic, which sees patients up to 22 years
of age. Recruitment will also occur at various medical
offices specializing in digestive disturbances. Participants
will also be recruited through community resources,
such as library and other public notice boards, as well
as websites of various IBS support groups and Craigslist.
We will also recruit participants from press releases sent
to surrounding areas through the UCLA Health Sciences
Media Relations department. Figures at the UCLA Divi-
sion of Digestive Diseases and the PPP suggest that
approximately 15 IBS patients per month will be
recruited in the appropriate age group. Private practice
digestive specialists in Los Angeles who have agreed to
refer to the project can refer an additional 18 patients
with IBS per month in the targeted age range.
The study administrator will meet with health care
providers, staff, and support group leaders to inform
them about the project and ask them to distribute and
post flyers about the study. The flyers will describe the
project and ask interested volunteers to call in to estab-
lish their eligibility. Effort will be made to recruit the
patient sample to be broadly representative of the gen-
eral population of IBS patients in the targeted age range.
Early epidemiological data examining the racial/ethnic
composition of IBS in a Southern California Health
Maintenance Organization (HMO) suggest that approxi-
mately 82% of patients will be White (non-Hispanic), 8%
Hispanic, 3.5% African American and 1% Asian [81].
Adult women are twice as likely to be affected, and sex
differences in IBS generally begin in late adolescence
[81]. The study is therefore likely to have a greater num-
ber of female patients. Recruitment efforts will attempt
to reflect the demographic composition of the Greater
Los Angeles area which is estimated to be approximately
75% White, 13% Asian, 10% African-American, 1%
American Indian/Alaska Native, and 1% Native Hawai-
ian/Other Pacific Islander.
Intervention
Iyengar yoga program
The poses to be included in this intervention are based
on the teachings of BKS Iyengar. They will include
supine poses, passive backbends, standing poses, and
supported inversions (e.g., Down Dog on Ropes with
chair; Rope headstand; Chair backbend on two chairs;
Chair shoulder stand; Chair Halasana; Setubandha Sra-
vangasana on Bench; Viparita Karani; Supta Baddhako-
nasana; and Supta Pada Ghustasana). All will be done
with props as needed. Young IBS patients will be taught
an IY practice that is specifically designed to address
their abdominal issues. The yoga poses will be done
with the aid of props (blocks, bolsters, chairs, straps,
and blankets) to reduce tension and strain, promote cir-
culation, and reduce apprehension of pain. The practice
will help bring awareness to habitual patterns of holding
tension, as well as increase range of motion and
strength. Students will learn to tolerate increased sensa-
tion without gripping and creating stress as they develop
deeper states of relaxation and calm. The intervention
will be conducted by an experienced IY teacher. At the
end of the 6-week IYP, participants who ask for referrals
to IY studios/teachers in the community will be given a
list of referrals. Participants will be provided with props
during week 3 to begin an informal home practice, if
they wish. All home practice as well as post-IY classes
will be monitored during the weekly monitoring form
and at follow-up.
Dose
The proposed IYP will be administered twice a week for
1.5 hours duration per session for 6 weeks. The length
of the IYP, class duration, and number of sessions was
based on our previous research using IY for young
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populations. We found significant effects after a 5-week
biweekly (90-minute sessions) IYP for depression in
young adults. However, these participants did not have
clinical levels of depression or a chronic condition, and
a longer intervention is appropriate for the present
patient population. Most recently, we conducted a
pilot study of a 6-week biweekly (90-minute classes)
IYP for young adults with RA [82] and found signifi-
cant reductions in pain and symptoms. It was therefore
deemed suitable to strive for the maximum benefit in
the shortest time likely to achieve benefit (6 weeks).
The weekly monitoring form (described below) will
track symptoms over the study period and help to
further inform studies about appropriate dose for
young people.
Yoga adherence monitoring board
A board will be created with the purpose of monitoring
instructor adherence to the study manual. The board
will consist of two senior IY teachers, who will conduct
ratings for teacher adherence by reviewing notes from
the classes. A research assistant will attend a random
selection of 25% of classes to note poses completed, use
of props, and any modifications or difficulties experi-
enced. Using a checklist, the board will rate the extent
of adherence to the yoga manual.
Laboratory pain task
The following task designed to measure visceral sensitiv-
ity will be administered in the PPP laboratory both at
baseline and then post-intervention following the IY
intervention/control groups.
Water load task
(WLT) to assess visceral sensitivity. Visceral sensitivity
tasks are designed to challenge patients for sensitivity to
visceral sensations. Walker and colleagues [83-85] devel-
oped the Water Load Pain task, which creates visceral
sensations similar to pain episodes in children with
abdominal pain. Water is administered orally as a single
trial of visceral sensation of abdominal discomfort. This
task correlates with the threshold for pain/discomfort
measured using an electronic barostat and has been
shown to be safe in healthy and clinical samples of
adults and children; and it is far less intrusive than
other measures of visceral sensitivity, such as rectal dis-
tension [86,87]. After a two-hour fast, subjects will be
asked to drink non-caloric, non-carbonated filtered
water at room temperature in as large a quantity as pos-
sible until s/he feels completely full or reaches a limit of
intolerability with an uninformed ceiling of 15 minutes.
Subjects will be informed that this is ‘not a race.’ Sub-
jects will be blinded as to the total volume ingested.
The time (seconds) elapsed from the beginning of water
ingestion until the subject stops drinking will be
recorded.
Measures
To assess the outcomes and mediators depicted in the
conceptual model (Figure1)
Primary outcomes
Questionnaires at baseline, post-treatment, and follow-up
1. IBS symptoms will be measured using the IBS sever-
ity scoring system (IBS-SSS) [88]. The scale measures
the sum of the participant’s evaluation on a 100-point
scale of each of five items: severity of abdominal pain,
frequency of abdominal pain, severity of abdominal dis-
tension, dissatisfaction with bowel habits, and interfer-
ence with quality of life. The IBS-SSS has acceptable
reliability and validity and is recommended for use in
outcome studies [89]. It takes approximately 5 minutes
to complete. Those younger than 18 will also receive
the abdominal symptoms sub-scale of the Child Somati-
zation Inventory (CSI). The CSI [90-93] measures per-
ceptions of nonspecific somatic symptoms. Individuals
rate how much they are bothered by each of 24 symp-
toms (e.g., headaches) during the last 2 weeks using a 5-
point scale (not at all to a whole lot). It takes less than
5 minutes to complete.
2. IBS pain will be measured with the Abdominal
Pain Index comprising five items assessing the fre-
quency, duration and intensity of pain episodes over the
previous 2 weeks. Good reliability and validity have been
reported [94].
3. Global Improvement will be assessed with the
Global Improvement Scale (GIS). This scale asks parti-
cipants “Compared to the way you felt before you
entered the study, have your IBS symptoms over the
past 7 days been from (1) = substantially worse, to (7) =
substantially improved [95]“. Global improvement is
noted for patients endorsing moderately or substantially
improved status. The scale shows adequate reliability
and validity [95]. Global improvement, in addition to
symptom severity, is recommended as a primary end-
point in IBS therapy trials [96]. The scale takes less than
1 minute to complete.
4. Health Related Quality of Life will be assessed
with the Health Related Quality of Life - Short Form-
36 (SF-36) [97] a generic core HRQOL measure yielding
an 8-scale profile of functional health and well-being.
The SF-36 performs well in an absolute sense and com-
paratively better than other HRQOL measures in terms
of reliability, validity, and lightness of respondent/
administrative burden [98]. It can be completed in 5-10
minutes and has been validated in children as young as
10 years of age [99].
Secondary outcomes
1. Functional Disability Index (FDI) [92] is a 15-item
measure assessing perceived difficulty in physical and
psychosocial functioning in the past 2 weeks due to
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physical health. Items are rated on a 5-point scale (no
trouble to impossible). It takes less than 5 minutes to
complete.
2. Visceral Sensitivity Index (VSI) is a reliable, valid
measure of gastrointestinal symptom-specific anxiety
[100]. It has 15 items assessing anxiety related to gastro-
intestinal sensations that are rated on a 6- point scale
from strongly agree to strongly disagree and takes less
than 5 minutes to complete.
3. Laboratory assessment at baseline and post-
treatment
Visceral pain sensitivity will be assessed via the
water load task, a measure of visceral pain. Laboratory
pain tasks provide a standardized, controlled way of
assessing pain sensitivity. The laboratory procedure will
take approximately 30 minutes.
Self-report and behavioral pain sensitivity 1. Pain
Intensity: Self-report ratings of pain intensity will be
recorded on a 10 cm vertical visual analog scale (VAS)
used to represent a continuum from no pain at all to
worst pain imaginable. The VAS has been widely used
as a valid and reliable measure of pain intensity with
children [101] in experimental and clinical pain studies.
2. Pain Tolerance: Maximal water intake (mL),
adjusted for BMI, will be recorded. Tolerance represents
a behavioral measure of pain response.
3. Pain Discomfort: Subjects will be asked to rate their
discomfort using the VAS to represent a continuum
from no discomfort at all to worst discomfort imagin-
able. The measure will assess the affective component of
the pain. Participants will be asked ‘how much does
your stomach feel bad or uncomfortable?’
4. Anticipatory Anxiety: Before each pain task, sub-
jects will use the vertical VAS automated slider to rate
how anxious or nervous they are about performing the
upcoming task, in response to the question ‘how ner-
vous, afraid or worried are you about the task?’
5. GI and Non-GI Symptoms: The Symptom Emotion
Report is a 21-item measure developed by Dr. Lynn
Walker’s lab that measures GI (e.g., nausea/upset sto-
mach) and non-GI (e.g., tired, upset) symptoms experi-
enced immediately before and after the WLT on a
5-point numerical scale of 0 (Not At All) to 4 (A Whole
Lot). Williams et al. [102] found that GI symptoms
reported during abdominal pain episodes significantly
predicted GI symptoms experienced following the WLT.
Psychospiritual functioning
1. Self-efficacy will be assessed with the Pain Self-
Efficacy Questionnaire (PSEQ) [103], a brief self-
report of self-efficacy for functioning despite chronic
pain. The scale consists of 10 items, takes 2 minutes to
complete, and asks about functioning when in pain;
functioning domains include activities related to
school, friends, family and work (including household
chores). Acceptable reliability and validity have been
reported [103].
2. Pain Catastrophizing will be assessed with the
Pain Catastrophizing Scale (PCS) [104] a 13-item self-
report instrument based on the catastrophizing subscale
of the Coping Strategies Questionnaire [105]. Respon-
dents select one of five response options (not at all to
all the time) indicating the degree to which they experi-
ence each item (i.e. “When I’m in pain, it’s terrible and I
think that it is never going to get any better”). This
measure takes less than 5 minutes to complete.
3. Mood will be evaluated using the Brief Symptom
Inventory 18 (BSI-18) [106]. Respondents rate how
often they have experienced anxiety, somatization, and
depressive symptoms within the past 7 days on a 5-
point scale ranging from not at all to extremely. The
BSI-18 has shown adequate to good internal consistency
(a range = .74 - .89) and validity [106]. The BSI-18
requires a 6th grade reading ability and takes approxi-
mately 5 minutes to complete. Children under 18 years
will be administered the Revised Child Anxiety and
Depression Scale (RCADS) [RCADS; [107,108]], a 47-
item adaptation of the Spence Children’s Anxiety Scale
(SCAS) [SCAS; [109,110]]. This measure assesses chil-
dren’s report of symptoms corresponding to selected
DSM-IV anxiety disorders and depression. This measure
takes 10 minutes to complete.
4. The Chronic Pain Acceptance Questionnaire
(CPAQ) [111] is a 20-item measure to assess acceptance
of chronic pain. The CPAQ has two subscales: Activity
Engagement assessing patients’ participation in activities
regardless of pain and Pain Willingness, assessing
absence of attempts to control or avoid pain. The
CPAQ has acceptable reliability (a = .78-.82) and valid-
ity [111]. It takes approximately 5-10 minutes to com-
plete and is suitable for older adolescents as young as
16 years of age.
5. Mindfulness will be assessed using the Mindful-
ness Attention Awareness Scale (MAAS) [76], a 15-
item measure rated on a 6-point Likert scale. Internal
consistency is high (a = .82) and the scale has accepta-
ble convergent and discriminant validity [76]. The scale
has been used with adolescents and young adults [112]
and was initially developed with participants aged 17
years and above. It takes approximately 5 minutes to
complete.
Exploratory mediators
Laboratory physiological responses at baseline and post-
treatment
Physiological responses Noxious stimuli such as pain or
emotional distress are known to activate the neuro-hor-
monal stress response [113]. The stress response is
modulated primarily by corticotropin releasing hormone
Evans et al. Trials 2011, 12:15
http://www.trialsjournal.com/content/12/1/15
Page 11 of 19
(CRH) and the autonomic nervous system. Pain has
been shown to activate the hypothalamus (hormonal
response) and the periaqueductal gray (autonomic ner-
vous center) [114]. The overall physiologic expression of
the stress response is manifested from a balance
between hormonal influences, sympathetic tone, and
parasympathetic tone. The acute stress response is char-
acterized by increase in heart rate, blood pressure,
respiratory rate, skin conductance, and cortisol.
Autonomic responses Autonomic arousal will be deter-
mined from measures of skin conductance, heart period,
respirations, and blood pressure recorded continuously
during the lab sessions using a BIOPAC MP150 record-
ing system (BIOPAC, Inc., Santa Barbara CA). Briefly,
skin conductance (SC), which reflects peripheral sympa-
thetic activity, is recorded using Ag/AgCl electrodes
secured to the volar surface of the first and third fingers
of the non-dominant hand. Heart period (HR) is
recorded using a two lead ECG from electrodes attached
to the jugular notch and over a lower rib. HR and SC
are sampled at 1000 hz and analysis of skin conductance
level, skin conductance responses, average HR, and heart
rate response during each task is computed using BIO-
PAC software (for peak detection and averages) and spe-
cialized software developed in our laboratories over the
past 10 years. Blood pressure is recorded using a nonin-
vasive system supplied by BIOPAC (NIBP100A), which
records radial artery waveform from a non-occluding
wrist cuff. Using a patented algorithm the NIBP100A
system calculates accurate systolic, diastolic, and mean
pressures and has been validated against arterial record-
ings. Respiration is recorded using an abdominal belt
and used to check for unusual breathing patterns that
might impact interpretation of the other measures.
Heart rate variability (HRV) is determined from the
interbeat intervals using specialized spectral analysis
software developed for this purpose [115,116], which
produces separate area and peak power measurements
for the low frequency (parasympathetic and sympathetic
influences) and high frequency (parasympathetic or
vagal) components of heart period. Heart rate variability
will be assessed by including a measure of respiration
(to calculate respiratory sinus arrhythmia). Boyce and
colleagues [117] have established the reliability and
validity of this system for physiological recording in chil-
dren as young as 3. Cardiac vagal tone is also estimated
using a software filter to detect respiratory sinus
arrhythmia (RSA, Delta-Biometrics, Bethesda, MD). RSA
is the normal variation in heart rate occurring in syn-
chrony with the inspiratory and expiratory phases of the
respiratory cycle. ANS variables will include resting and
maximum change values during each task for: blood
pressure, skin conductance, high frequency HRV (vagal
tone), and sympathetic balance (HF/LF).
Cortisol Salivary cortisol, a neuroendocrine marker of
HPA axis reactivity has long been used in the study of
the psychobiology of stress [118]. Salivary cortisol will
be used as a physiological evaluation of general stress,
and whether patients’ stress response changes as a result
of the IYP. Collection of cortisol through saliva is a
non-invasive way of measuring HPA axis activity and is
correlated with unbound serum levels [119]. Fifteen
minutes prior to the first collection, participants will be
asked to rinse their mouth with water to prevent con-
tamination of sample by food debris. Subjects will also
be instructed not to eat or drink 1 hour prior to the ses-
sion to minimize sample contamination. Participants will
be instructed to imagine smelling and eating their favor-
ite food and to begin to allow the saliva to pool at the
bottom of their mouths. Saliva samples will be collected
with small straws placed in the mouth so that the saliva
can easily be collected into a cryovial. We will aim to
collect 1.5 mL of saliva at each collection from each par-
ticipant. Saliva is then frozen and sent to the UCLA
CNS Endocrine Core laboratory for quantification. Sali-
vary cortisol will be collected before and after each
laboratory session as well as the morning of the labora-
tory assessments. Each laboratory session will involve
three samples: immediately upon arrival (initial baseline
measure); directly after completing the questionnaires
(second baseline measure); and 20 minutes after the end
of the visceral sensitivity task (maximal stress response).
A meta-analysis of acute psychological stress reveals
that the overall peak cortisol response occurs 21-40
minutes from onset of an acute stressor level [120]. One
of the most prominent features in studies of adrenocor-
tical responses under physical and psychological stimu-
lation is the large variation in both baseline levels and
in response magnitude between subjects. We intend to
assess salivary cortisol twice before the pain tasks to
control for individual differences at baseline and to cap-
ture the possible effects of anticipatory stress on cortisol
elevation. These multiple assessments should reflect the
overall magnitude of cortisol changes [121].
Additional measures
1. An expectation question will be administered after
assignment and before treatment to assess whether
treatment expectation impacts outcomes. Subjects will
be asked to rate on a scale of 0 to 10 ‘How much do
you think the treatment will benefit you or improve
your IBS symptoms?’
2. The weekly monitoring form will include items
related to mood, IBS pain, symptoms and functioning
and use of any new interventions. The form will be
administered by telephone or e-mail at the end of each
week to both groups. The weekly monitoring form is an
important tool in the study design, given that IBS is a
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condition without clear biomarkers to assess illness
severity and progression, self-reported pain, symptom
and functioning tools will form the basis for assessment
of appropriate dose. The form will also ensure the con-
trol group does not introduce any new mind-body treat-
ments during the intervention.
3. Females will receive a question that asks about their
last menstrual period (LMP) to control for potential
varying pain sensitivity over cycle phase. Self-reported
menstrual cycle length is a common, non-invasive clini-
cal marker for reproductive function [122].
Participant Burden: It is anticipated that the laboratory
procedure and the standardized questionnaires will take
1.5 hours at baseline, and 1.5 hours post-treatment. The
2-month follow-up is expected to take 40 minutes. The
weekly monitoring form will take approximately 8-10
minutes each week.
Data management
A unique ID will be assigned to each patient for the
purpose of protecting anonymity, and no patient identi-
fiers will be included in the dataset. Data from the stan-
dardized quantitative measures will be entered into an
Excel database then moved into SPSS, which will be
used for the statistical analyses. Initial data cleaning and
preparation will include evaluation of the distributions,
outlier/error detection, logical and range checking and
creation of derived variables. Sensitivity analyses will be
conducted after imputing for missing data.
Data analyses
Each stage of data analysis detailed below will be carried
out separately for adolescent (14-18 yrs) and young
adult (19-26 yrs) sub-groups. If no differences are
found, the groups will be combined. It is unlikely that
differences will emerge in terms of feasibility, efficacy or
safety, but a separate analysis of sub-groups will ensure
that findings are generalizable across the ages studied.
Once the data set has been cleaned and examined for
skewness, exploratory data analyses will be conducted
using univariate methods to describe the variables of
interest and bivariate techniques to characterize their
interrelationships within our sample. Continuous vari-
ables will be summarized over time in each group using
means, medians, range, interquartile range and standard
deviations. Cross tabulated frequencies will be given for
all discrete variables by group and time. Both parametric
and non-parametric correlations will be reported. Expec-
tation ratings will be correlated with primary outcomes
to determine whether patient expectations were related
to post-intervention symptoms.
For Hypothesis 1: IY will be safe, acceptable and fea-
sible: more than 80% of subjects will complete the train-
ing program, the frequencies of drop-outs for the IYP
and control groups will be examined. Attrition rates will
be compared between the yoga and control groups;
demographics and baseline values of functioning
between those who complete the protocol and those
who do not will also be compared. If drop-outs are ran-
dom, then the results may be considered unbiased. If
drop-outs are not random, the direction and magnitude
of potential biases will be considered.
To test Hypothesis 2: Participants in the IY group
will demonstrate significantly greater improvement in
IBS symptoms, global improvement and HRQOL appar-
ent immediately post-intervention and at the 2- month
follow-up. Consistent with recommendations regarding
analyses for randomized trials, analysis of covariance
(ANCOVA) will be used to test group differences [123].
The baseline scores of the outcome variables will be
entered as independent variables. The Next, analyses
will assess maintenance of treatment gains during the
follow-up period. Changes in IBS symptoms, HRQOL
and improvement across baseline, post-treatment and
follow-up will be evaluated using ANCOVAS. An
intent-to-treat (ITT) analysis on the primary outcome
measures will be conducted to confirm findings in treat-
ment completers by including all participants who
enrolled in the study, using the last observation carry
forward approach. Even if significant differences are
noted, consideration will be given to established mini-
mally clinically significant differences on outcome mea-
sures between the groups. Thus, in order to be
considered a clinically meaningful difference, partici-
pants must evidence a decrease in at least 50 points on
the IBS-SSS in comparison to controls.
To test Hypothesis 3: Participants in the IY group
will report significantly reduced visceral sensitivity, dis-
ability and improved psychospiritual functioning. The
same methods will be used as described above for
hypothesis 2. Similar analysis will be conducted to
examine changes in visceral sensitivity, disability and
psychospiritual functioning, including self-efficacy, cop-
ing, mood, acceptance and mindfulness from baseline to
post-treatment.
To test Hypothesis 4: As depicted in Figure1, Psycho-
spiritual-physiological outcomes will be explored as
mediators of the association between IY and improved
IBS outcomes. Regression analyses will be conducted to
determine whether these variables mediate treatment
outcome. The procedures outlined in Cohen and Cohen
[124] will be used to calculate residualized change
scores for IBS symptoms, global improvement, HRQOL
and pain sensitivity scores. Multiple regression analysis
will then be conducted with IBS symptoms, global
improvement, and HRQOL separately; change scores
(baseline minus post-treatment) will be regressed onto a
set of predictor variables including group (yoga vs.
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control), the mediator variable of interest (e.g., self-effi-
cacy), and the interaction between the mediator and
group. If evidence of mediation is found using the tradi-
tional Baron and Kenny approach - the Sobel test - a
statistical test for mediation will be conducted to calcu-
late mediation. Finally, exploratory analyses will be con-
ducted from the Weekly Monitoring data.
Sample size determination and power analysis
Based on our previous pilot work using Iyengar yoga for
patients with rheumatoid arthritis [82], we estimated
that yoga was likely to have a medium effect size on the
primary outcomes. For power calculations, a freely-avail-
able software for power calculations - G*Power 3- was
used to estimate the sample size needed for the esti-
mated effect size using a pre/post by group interaction.
Pairing a medium effect size with a range of correlation
values (.10 to .50) for baseline and follow-up scores
resulted in power calculations ranging from 60 to 34
total subjects. These calculations used a Type I error
rate of a = .05, and statistical power of 0.80 (the Type II
error rate, 1- b). We settled upon the middle value of 47
total subjects. Assuming a 20% attrition rate, it was esti-
mated that 60 total subjects would need to be recruited
(30 per group).
Protection of human subjects
This study was approved by the Medical Institutional
Review Board 1 (MIRB1) within the Office of the
Human Research Protection Program at UCLA (IRB
Number 09-05-070-01). The study will be carried out in
compliance with the Helsinki Declaration.
Risks to subjects
Yoga is generally regarded as safe and adverse effects are
rare, especially within the Iyengar program in which
props are used for support and teachers undergo vigor-
ous training for certification. However, a number of case
reports have indicated adverse events following yoga,
specifically, the presence of subcutaneous emphysema
[125] and shortness of breath and chest pain [126].
Nevertheless, these events were in response to intensive
pranayama, or breathing exercises, with the shortness
of breath case experiencing difficulty following kapalab-
hati pranayama involving strong forced breaths which
may push the body to physiologic extremes [126]. Such
intensive breathing techniques will not be used in this
yoga intervention. Great care will be taken in developing
the yoga program to ensure that bodily systems are not
stressed.
The laboratory pain component of the study presents
some potential risks to subjects. During physiological
assessments, some subjects may be bothered by arm
cuff inflation for blood pressure measurement. However,
all participants should have had experience with these
procedures from routine medical check-ups.
Additionally, some physical discomfort may be experi-
enced during the water load task. However, subjects are
in control of how long the task takes–they may stop the
procedure at any time and the experimenter will be in
the room at all times to provide supervision and sup-
port. Also, the experimenter will discontinue the study
if distress is observed in the subject whether or not the
subject expresses distress. During the procedure, sub-
jects may experience some potentially discomforting
anxiety. However, the anxiety will be transitory and is
unlikely to exceed levels of fearfulness that subjects
experience naturally when unexpectedly encountering
mild pain stimuli in their own environment. In past
pain studies, we have not encountered any anxiety-
related problems. Participants may also feel uncomforta-
ble disclosing personal information about their mood
and symptoms on study questionnaires.
Protection against risk
Privacy and confidentiality
Confidentiality will be maintained by the use of unique
identification numbers. All data, as well as participant
lists, will be kept in locked file cabinets with access
restricted to research staff. All data forms will have sub-
ject ID only.
Safety aspects of the study design and conduct
The major potential risks from the yoga class are strains
or injuries. We will minimize these risks by conducting
the yoga intervention in the safest manner possible. A
progressive series of poses has been developed for this
trial; this gradual progression, tailored to the partici-
pants, is designed to avoid injury. In addition, props will
be used to support participants in more challenging
poses. The general safety parameters of the yoga pro-
gram are: 1) heart rate will not exceed moderate training
range (115 BPM) - we will ask participants to check
their pulse at the end of each yoga session during a
timed one-minute period and to report their heart rate
(anyone who remains at a rate of greater than 115 BPM
will be interviewed and assessed by a physician to deter-
mine if this is a consistent finding or if there may be
other isolated reasons for the tachycardia, such as a viral
illness); 2) attention will be paid to spinal safety; 3) bal-
ance will be carefully monitored (e.g., chairs are used to
assist balance as needed). Students will be given modifi-
cations of postures using props to accommodate for
individual differences and limitations and receive indivi-
dual attention if postures are too challenging.
To minimize potential risks or discomfort associated
with the laboratory tasks, an experimenter will remain
in the room for supervision and observation of subject
responses. If subjects show signs of acute distress (e.g.,
tearfulness), the experimenter will stop the experiment
and talk with the individual until he/she feels calmed.
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The patient can end the study participation or continue,
depending upon how he/she feels. The team has devel-
oped ways of carrying out laboratory pain research with
children to minimize threat and to make it an interest-
ing and pleasantly novel experience.
To minimize any potential risks or discomfort asso-
ciated with study assessments, all assessments will be
conducted in a private room. Participants will be
encouraged to raise questions or concerns at any time
and be reminded that they may withdraw at any time
without penalty. In addition, a clinical psychologist will
train all research personnel to identify and report any
history of abuse or risk for potential self- or other-harm
if this information is revealed in responses to question-
naires or during interviews, as required by the study
institution’s IRB.
Data and safety monitoring plan
The principal investigator will be responsible for main-
taining quality control over the data collection process
and for securing its confidentiality; she will oversee the
process of data collection and ensure that data is
reviewed for completeness and accuracy. Reviewed data
will be secured in locked file cabinets in the project
offices. During each of the treatment waves, potential
threats to the safety and well-being of participants will
be carefully monitored. If, for example, there is any
adverse change in the medical condition of participants,
the study physician will be immediately consulted and
the participant’s physician contacted to make arrange-
ments for treatment, if necessary.
The proposed project is a single site study with low
complexity and minimal toxicity risk. Nevertheless, a
safety monitoring committee is appropriate for oversight
of the research that includes safety officers who are IBS
experts.
Monitoring process
Study performance and safety monitoring will be con-
ducted. The list that follows shows the major items that
will be included in the monitoring reports. The safety
committee will receive bi-monthly summaries containing
information on each item in the list, presented in a
blinded manner. A trained research assistant will be in
charge of preparing reports for the safety committee. In
case of safety concerns (primarily about side effects),
requests by the committee for unblinded information
will be made to the study physican who will provide the
necessary information.
Content of safety reports
The following performance and safety characteristics will
be tabulated monthly and reported to the safety commit-
tee bi-monthly. Information on the date, time and nature
of any adverse events will be reported separately for the
yoga intervention and the visceral sensitivity task.
Performance summary:
1. Recruitment rates, including number of subjects
who are screened, percent eligible at each stage of
screening, reasons for non-eligibility, baseline visit
rates, and randomization figures
2. Demographics of screened and enrolled partici-
pants by treatment group
3. Adherence of participants to study treatment (i.e.,
class attendance)
4. Percent of participants evaluated at each follow-up
point and reasons for losses to follow-up
Safety summary:
Iyengar yoga intervention
1. Worsening of symptoms, as documented by the
weekly monitoring form
2. Possible side effects, including any cardiovascular
event during class
3. Injuries occurring in class or during home
practice
4. Any other unrelated, possibly related, and related
adverse events by subject
5. Attribution of adverse event to the study interven-
tion, determination of whether the adverse event
was expected or unexpected, and study adjustments
as necessary
Laboratory visceral sensitivity task
1. Possible side effects, including any cardiovascular
event
2. New pain that persists by the end of the lab
session
3. Any other unrelated, possibly related, and related
adverse events by subject
4. Attribution of adverse event to the study interven-
tion, determination of whether the adverse event
was expected or unexpected, and study adjustments
as necessary
Significance
Only one published study has examined the effects of IY
as a therapy for young people with chronic pain [51],
and methodological limitations preclude strong conclu-
sions from this prior work. The proposed study is inno-
vative as it will be the first controlled investigation of a
group-based, standardized intervention of yoga for
young people with IBS. IY is a tradition of yoga that is
unique in its emphasis on precise anatomical alignment,
use of supportive props, sequences of asanas (postures)
tailored for specific conditions, and a highly systema-
tized and rigorous teacher training system. In combining
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these elements, IY is likely to be a safe, standardized,
and reliable treatment suitable for clinical research. Few
studies have included young patients, or a control
group, as proposed here. Additional innovations include
the testing of psychospiritual and physiological mechan-
isms of action within a biopsychosocial model, the use
of an experimental paradigm to examine patients’ visc-
eral pain sensitivity following yoga, as well as assessment
of ANS arousal and HPA axis reactivity via salivary cor-
tisol. No previous studies have included a standardized
assessment of visceral (water load) pain to examine out-
comes following a mind-body intervention in young IBS
patients.
The study will serve to broaden the body of research
on the use of yoga to address chronic pain conditions.
Young sufferers of IBS represent an especially important
group to assist due to the likely longevity of their pain
and limitations. The minimal side effects of IY, espe-
cially compared to other current treatments, make it
attractive for a population who expect to be active in
work, study, and recreation. The IY intervention- if
found to be effective in improving IBS symptoms, qual-
ity of life, and reducing pain- could provide a self-help
tool for long-term use for young people with IBS. Preli-
minary findings from this study will inform larger-scale
investigations by determining effect size and thus sam-
ple sizes needed for future multi-center studies. The
results of this research will yield initial data needed as a
pre-requisite to a larger level evaluation of an IY inter-
vention for IBS in adolescents and young adults includ-
ing estimates of intervention parameters (attrition rates,
response rates, confidence interval estimates of effect
size), variability in outcomes, willingness to accept ran-
domization, and potential sampling biases.
If shown in this study to significantly improve symp-
toms and functioning, further research could examine
additional psychobiological mechanisms that might be
responsible for these changes. For example, future stu-
dies should examine systemic pro-inflammatory cyto-
kines and/or a range of stress hormones that might
relate to changes in gut functioning, physical function,
and mood. IY has practical, heuristic value in that it can
be taught by the many trained teachers of IY once the
protocol has been established in this study, with such
applicability allowing broad access to this intervention.
Finally, by providing information regarding an evi-
denced-based intervention for IBS, data from a subse-
quent multi-centered IBS RCT may help support health
insurance coverage of specific yoga programs for
patients with IBS.
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